In an adult with plaque psoriasis, how should methotrexate be used compared to upadacitinib, including dosing, monitoring, and criteria for choosing one over the other?

Methotrexate vs Upadacitinib for Psoriasis

For moderate-to-severe plaque psoriasis, upadacitinib 15 mg daily achieves faster and more complete skin clearance than methotrexate, but methotrexate remains the first-line systemic agent due to established long-term safety data, lower cost, and guideline support, with upadacitinib reserved for methotrexate failures or when rapid clearance is essential.

Treatment Selection Algorithm

Start with Methotrexate if:

• First systemic therapy attempt
• Cost is a primary concern (methotrexate costs significantly less 1)
• Patient accepts weekly oral dosing and regular monitoring
• No contraindications (severe hepatic/renal impairment, pregnancy planning)
• Moderate disease where 8-12 week response time is acceptable

Choose Upadacitinib if:

• Failed methotrexate after 12-16 weeks 1
• Rapid disease control needed (upadacitinib achieves PASI 75 by week 12 in 57% vs slower methotrexate response 2)
• Patient refuses injectable biologics
• Concomitant psoriatic arthritis with inadequate methotrexate response 3
• Patient cannot tolerate methotrexate monitoring requirements

Methotrexate Dosing and Monitoring

Dosing Protocol 1:

• Start: 5-15 mg weekly (healthy adults); consider 2.5-5 mg weekly if renal impairment
• Target: 25 mg weekly is more effective than 10 mg weekly—achieves PASI 75 faster (7.9 vs 9.5 weeks) and higher PASI 100 rates (69% vs 30%) 4
• Folic acid: Mandatory supplementation to reduce toxicity 1
• Route: Subcutaneous administration may improve bioavailability and efficacy over oral, though costs more 5

Monitoring Requirements 1:

Weeks 1-4:

• CBC, LFTs, renal function every 7-14 days

After stabilization:

• CBC, LFTs, renal function every 2-3 months
• Serum PIIINP (procollagen III peptide) every 3 months for liver monitoring
• Refer hepatology if: PIIINP >8 mg/L on two occasions, OR three measurements >4.2 mg/L in 12 months, OR >10 mg/L once

Baseline and ongoing:

• Chest X-ray if age >40 and smoker, or respiratory symptoms
• Pneumococcal vaccine and annual influenza vaccination 1

Critical Patient Warnings 1:

• Weekly dosing only—daily dosing causes fatal toxicity
• Seek urgent care for: fever, mouth ulcers, unexplained bruising/bleeding, severe fatigue, dark urine, breathlessness
• Strict contraception required
• Limit alcohol intake
• Avoid NSAIDs and trimethoprim (increase methotrexate toxicity)

Upadacitinib Dosing and Monitoring

Dosing Protocol 3:

• Psoriasis dose: 15 mg once daily (FDA-approved for psoriatic arthritis; used off-label for plaque psoriasis)
• No dose adjustment needed for renal impairment
• Contraindicated in severe hepatic impairment (Child-Pugh C)
• No drug interaction with methotrexate 3

Monitoring Requirements 3:

Baseline:

• CBC, comprehensive metabolic panel, lipid panel
• Tuberculosis screening
• Hepatitis B/C screening

During treatment:

• CBC, LFTs every 12 weeks initially
• Lipid panel at week 8, then every 12 weeks
• Monitor for: neutropenia (<1000 cells/mm³), lymphopenia (<500 cells/mm³), ALT/AST elevations (>3× ULN), CPK elevations (>5× ULN)

Critical Safety Concerns 6, 3:

• Black box warnings: Serious infections, malignancy, cardiovascular events, thrombosis
• Increased VTE/PE risk in patients with cardiovascular risk factors (based on tofacitinib data, class effect concern)
• Herpes zoster occurs in 1.1% (consider vaccination)
• Lipid elevations: Mean LDL increases 14.8 mg/dL, HDL increases 8.2 mg/dL—LDL/HDL ratio remains stable 3
• Acne and bronchitis more common than placebo

Comparative Efficacy

Network Meta-Analysis Data 7:

• Anti-IL17 biologics (bimekizumab, ixekizumab) rank highest for PASI 90
• Methotrexate ranks lower than all biologics but superior to apremilast
• JAK inhibitors (tofacitinib class) show intermediate efficacy—faster onset than methotrexate but lower peak response than IL-17/IL-23 biologics

Head-to-Head Comparison 2:

• PASI 75 at week 12: Tofacitinib 57.1% vs methotrexate 42.9%
• PASI 90 at week 16: Tofacitinib 57.1% vs methotrexate 19.0% (p<0.05)
• Time to response: Tofacitinib faster, but methotrexate shows cumulative improvement over 16 weeks

Common Pitfalls and Caveats

Methotrexate:

• Daily dosing error is potentially fatal—emphasize weekly dosing repeatedly
• Monitoring non-compliance leads to undetected hepatotoxicity—patients unable to attend regular labs should not receive methotrexate 1
• Therapeutic benefit delayed 3-12 weeks—counsel patients to avoid premature discontinuation 1
• Alcohol and NSAIDs significantly increase hepatotoxicity risk

Upadacitinib:

• Off-label use for plaque psoriasis—only FDA-approved for psoriatic arthritis (explain to patients) 3
• Cardiovascular risk stratification essential before prescribing—avoid in patients with significant CV risk factors given class VTE concerns 6
• Not a biologic—different mechanism than IL-17/IL-23 inhibitors; broader immunosuppression via JAK1 inhibition
• Cost barrier—significantly more expensive than methotrexate; insurance may require methotrexate failure documentation

Practical Decision Framework

Use methotrexate first unless contraindicated or patient-specific factors favor upadacitinib. The 2016 British guidelines 1 provide robust methotrexate protocols, while upadacitinib lacks psoriasis-specific approval and long-term safety data in this population. Methotrexate's 40+ year track record, low cost, and guideline support make it the rational first choice despite slower onset and more intensive monitoring.

Switch to upadacitinib after documented methotrexate failure (inadequate response at 12-16 weeks or intolerable toxicity). The 2021 JAK inhibitor consensus 6 and FDA label 3 support this approach for immune-mediated inflammatory diseases. Upadacitinib offers oral convenience without injections, faster clearance than methotrexate 2, and efficacy in refractory cases 8.

Consider biologics (IL-17/IL-23 inhibitors) over upadacitinib if maximal efficacy is the priority, as network meta-analysis shows superior PASI 90 rates for bimekizumab, ixekizumab, and risankizumab 7. Upadacitinib fills the niche for patients preferring oral therapy who have failed methotrexate but want to avoid injections.